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Human embryonic stem cells (hESCs) are one of the most interesting cell types for tissue engineering, cell
therapy, basic scientific research, and drug screening. Fast advancement in these areas requires the availability of
large amounts of safe and well-characterized hESCs from hESC banks. Therefore, optimized freezing protocols,
allowing the cryopreservation of large amounts of hESC without direct contact with liquid nitrogen, need to be
established. In this study, 6 different cryoprotector combinations [dimethylsulfoxide (DMSO), ethylene glycol,
and hydroxyethylstarch (HES)] combined with 2 different application methods were screened with the VUB01
cell line, to establish a new slow-freezing protocol with high recovery rates and a good expansion capacity. Our
best conditions were confirmed in 4 other hESC lines: H1, H9, 181, and UGent2. To our knowledge, this is the
first time that HES is evaluated as a cryoprotector for hESCs. The use of 5% DMSO + 5% HES combined with a
new detachment protocol leads to efficient hESC cryopreservation. This protocol involves treating the hESC
colonies with cell dissociation solution, a mild dissociation solution uncommonly used for hESC culture. A
recovery ratio ranging from 45.5% to 168.2% was obtained, and these were significantly different from the other
tested conditions (Student’s t-test, P < 0.05). The cryopreserved hESCs were morphologically comparable to
control cells, exhibited a good expansion profile, were positive for pluripotent expression markers, and could
still differentiate into the 3 germ layers. This new protocol allows efficient and economical hESC cryopreser-
vation, ideal for hESC banking.
Introduction
Since the first derivation of human embryonic stemcells (hESCs) [1], scientists have been researching these
cells and discovering their importance, capabilities, and
complexity. These unspecialized cells are capable of long-term
self-renewal in vitro while retaining their capacity to differ-
entiate into all cell types from the 3 germ layers, an ability
called ‘‘pluripotency.’’ These remarkable cell characteristics
turn hESCs into one of themost interesting cell types for tissue
engineering purposes, advancements in drug screening, dis-
coveries in basic scientific research, and the conduction of
developmental studies [2,3]. One prerequisite for fast pro-
gression in these areas is the availability of large amounts of
well-characterized hESCs from hESC banks. The banking of
hESCs for research and future clinical applications requires
optimized cryopreservation and thawing protocols.
Currently, 2 techniques are applied for the cryopreserva-
tion of hESCs: vitrification and slow freezing–rapid thawing.
Vitrification is favored by several groups for the cryopres-
ervation of hESCs [4–7]. Using open pulled straw methods,
survival rates of 70%–90% have been reported. However,
there are several disadvantages preventing the widespread
use of this technique. First, high concentrations of cryopro-
tectors, which are cytotoxic above 4C, are needed to rapidly
obtain the solidified glass-like state [8,9]. Second, the pro-
cedure requires serial dilutions in different cryoprotector
media, which must be performed fast and precisely.
Consequently, this task needs to be performed by trained
specialists and is, in itself, very labor intensive. Additionally,
vitrification is also mostly performed in open pulled straws.
In the open straw, contact between the liquid nitrogen and
the cells is established, which carries the risk of bacterial and
fungal contaminations [10]. A major disadvantage, however,
is that only a low amount of hESC colonies can be vitrified
per run. Hence, scaling-up the experiment to freeze bulk
quantities of hESCs poses inherent problems.
In contrast, during the slow-freezing procedure, only low
amounts of cryoprotector are added to the solution, no serial
dilutions or laborious tasks need to be performed, and higher
amounts of hESCs can be frozen in 1 run in a closed cryovial.
The major difficulty in slow freezing is determining the right
cryoprotector combination and concentration to adequately
stabilize the cells and the ice nucleation during the freezing
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process. Many scientists have looked into slow-freezing
protocols for hESCs as an alternative for vitrification [11–14].
Dimethylsulfoxide (DMSO) is the most popular cryopro-
tector for hESC slow freezing, often in combination with fetal
bovine serum (FBS) and ethylene glycol (EG). Other scientists
are exploring the cryopreservation of adherent hESCs [5,15].
Recently, most cryopreservation protocols focus on the ad-
dition of a Rock inhibitor (Y-27632) during the different
stages of the freezing process as a means to ameliorate the
recovery rate of the hESCs [16–20].
In this article, 6 different cryoprotector combinations of
DMSO, hydroxyethylstarch (HES), and EG [14,21,22] were
tested. Cryoprotectors are added during the freezing process
to have a better control over the ice formation and cell
damage that occurs because of the accumulation of intra-
cellular and extracellular ice crystals. There are 2 types of
cryoprotectors—intracellular and extracellular cryoprotectors—
both with a different impact on the freezing process. In-
tracellular cryoprotectors, such as DMSO, EG, and glycerol,
have a low molecular weight and thus can penetrate the cell
membrane and gradually substitute the H2O present in the
cells. The osmolality of the cells is thereby increased, and
subsequently, the percentage of extracellular H2O that can
form ice crystals before reaching the osmotic equilibrium is
reduced and total dehydration of the cells is prevented
[8,10,23–25]. Extracellular cryoprotectors, such as polyvinyl
pyrrolidone, HES, polyethylene glycol, dextran, trehalose,
and sucrose, cannot penetrate the cell membrane and stabi-
lize the cell by forming a viscous glassy shell around its
surface [8,25]. By combining intracellular and extracellular
cryoprotectors, both the inner cell and the cell surrounding is
stabilized, which in theory should lead to a better cell sur-
vival once an ideal combination is found.
These cryoprotectors were tested in combination with 2
application methods and an optimized thawing protocol.
Our aim was to find an efficient cryopreservation method
with a high recovery ratio that allows freezing of large
amounts of hESCs while retaining their pluripotency and
expansion capacity.
Materials and Methods
Feeder preparation: mouse embryonic fibroblasts
Mouse embryonic fibroblasts (MEFs) originating from
MF1 mouse embryos between passage 0 and 4 were used as
a feeder layer to sustain the hESC culture. The MEFs were
treated with 10 mg/mL mitomycin C (Sigma Aldrich) for 3 h
to arrest mitosis and seeded at a density of 8,500 cells/cm2
on gelatin-coated tissue culture plates.
hESC standard culture protocol
The hESC lines used in these experiments were the VUB01
[26] (VUB), H1 (Wicell), H9 (Wicell), 181 (Karolinska Institute),
and UGent2 hESC line [27] (Department for Reproductive
Medicine, Ghent University Hospital, Gent, Belgium). The
hESCs were cultured on mitomycin-C inactivated MEFs on
tissue culture plates at 37C under 5% CO2. The hESC me-
dium consisted of 80% Dulbecco’s modified Eagle’s medium
(DMEM)-F12 (Invitrogen)+20% serum replacement (Invitro-
gen)+ 1mM l-glutamine (Invitrogen)+0.1mM nonessential
amino acids (NEAA) (Invitrogen)+0.1mM b-mercapto-ethanol
(Invitrogen)+4ng/mL basic fibroblast growth factor) (Milli-
pore). The medium was changed daily and the cells grew as
dense colonies. Weekly, the hESC colonies were split by mi-
crodissection using sharp glass-cutting pipettes.
hESC slow-freezing protocols
A large-scale slow-freezing setup was performed with the
VUB01 cell line. Two detachment protocols were applied to
obtain pure hESCs. In protocol 1, the hESC colonies were
detached as entire colonies with collagenase IV. In protocol 2,
the hESC colonies were detached with collagenase IV and
subsequently treated with a cell dissociation solution for
5min. Six different cryopreservation solutions were tested:
10% DMSO + 90% HM, 5% DMSO + 5% HES + 90% HM, 10%
DMSO + 10% HES + 80% HM, 10% EG + 90% HM, 5%
EG + 5% HES + 90% HM, and 10% EG + 10% HES + 80% HM.
After preparation, 1mL of the cryosolution with cells was
transferred to a cryovial (Cryo.S; Greiner Bio-One), cooled
slowly (cooling rate - 1.5C/min) to - 80C, and then stored
in a liquid LN2 storage device. HM medium consisted of 80%
DMEM-F12 (Invitrogen) + 20% serum replacement (Invitro-
gen) + 400mL HEPES. The best conditions were repeated with
the H1, H9, 181, and UGent2 cell line.
Thawing of hESCs
All experimental slow-freezing protocols were thawed in a
water bath of 37C, until an icy mass remained. Sucrose
(0.1M)–HM medium was added and incubated for 5min.
Then the cell suspension was centrifuged and plated out onto
fresh MF1 feeders.
Evaluation after thawing and data collection
All experiments were repeated in triplicate, and all vials
were kept for minimally 1 week in LN2. The amount of hESC
colonies, obtained from full-grown plates, was counted be-
fore freezing, after thawing, and at 7 days of culture post-
thawing. The hESC colonies were morphologically evaluated
and counted using a gradual scoring system [5,28] on an
inverted phase-contrast light microscope with objective
4 · (Olympus inverted Research System Microscope IX81).
For each counted colony number, an uncertainty degree of
5% was taken into account. This degree of uncertainty was
established after repeated counting experiments of the same
plate and used to determine the error bars in the statistical
graphical representations [29]. Only grade A ( > 80% undif-
ferentiated) and grade B (between 50% and 80% undiffer-
entiated) colonies were selected for further use in the
evaluation as these are the only colonies capable of gener-
ating new pluripotent colonies in the next passage. There-
fore, the recovery rate was calculated as follows: the amount
of Grade A +B colonies at day 7 postthawing versus the
amount of frozen Grade A +B colonies. The Student’s t-test
was used for determining significant differences between the
obtained amounts of colonies after freezing. A P value of
< 0.05 was considered significant.
hESC: expansion profile
The thawed hESCs were followed for a minimum of 3
passages, to evaluate changes in their expansive behavior. By
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use of the same counting and gradual scoring system, as
mentioned earlier, combined with the known split ratio, the
total amount of colonies was calculated for each passage. The
mean of the total amount of colonies (experiments performed
in triplicate) was plotted.
hESC: size analysis
For size analysis, digital images were recorded during the
cryopreservation experiments. A minimum of 100 randomly
selected hESC colonies or clumps were measured using the
Excellence software of the Olympus microscope system
(Olympus Inverted Research System Microscope IX81,
brightfield, objective 4· ). Mann–Whitney test was per-
formed to evaluate statistical differences. A P value of < 0.05
was considered significant.
Immunocytochemical analysis of hESC colonies
hESC pluripotency was determined at passage 5 by im-
munostaining for SSEA-3, SSEA-4, TRA 1-60, TRA 1-81, and
Oct4 (isoform 4A) (antibodies from Santa Cruz Biotechnol-
ogy, Inc.) and by alkaline phosphatase staining (BCIP/NBT
Liquid Substrate System by Sigma). For the immunostaining,
colonies were fixed in 1% paraformaldehyde for 10min,
washed with phosphate-buffered saline (PBS), and blocked
with blocking serum (PBS/5% normal rabbit or goat serum/
0.2% Tween) for 30min. Primary antibodies used were rat
monoclonal anti-SSEA-3 (IgM 1/200), mouse monoclonal
anti-SSEA-4 (IgG 1/500), mouse monoclonal anti-TRA 1-60
(IgM 1/100), mouse monoclonal anti-TRA 1-81 (IgM 1/50),
and mouse monoclonal anti-Oct4 (IgG 1/100). After 1 h of
incubation, the cells were washed with PBS and incubated
with the secondary antibody (FITC-labeled goat anti-mouse
IgM 1/500 or biotin labeled rabbit anti-mouse IgG) for
30min. In case a biotin-labeled secondary antibody was
used, visualization was achieved with streptavidin–FITC
coupling (30min). After washing, the cells were covered with
PBS and evaluated by fluorescence microscopy (Olympus
inverted Research System Microscope IX81, GFP filter, CellM
software).
hESC embryoid body formation
Plates with full-grown hESC colonies were selected. The
hESCs were detached from the feeder layer by incubation
with collagenase IV solution (1mg/mL) for 30–40min. The
colonies were pelleted by centrifugation for 3min at 90 g,
resuspended in embryoid body (EB) medium, and trans-
ferred to shaker flasks. The EB medium consisted of 80%
DMEM-F12 (Invitrogen) + 20% FBS (Invitrogen) + 1mM l-
glutamine (Invitrogen) + 0.1mM NEAA (Invitrogen) and
0.1mM b-mercapto-ethanol (Invitrogen). EBs were formed at
passage 10 and cultured for 21 days in these settings.
Real-time RT-PCR analysis of hESC colonies
and EBs
The colonies were detached from the feeder layer using
collagenase IV solution (1mg/mL; Invitrogen) for 30–40min,
collected, and centrifuged at 90 g for 3min. After removal of
the supernatant, TRI reagent was added to obtain lysis of the
cells. The RNA was isolated using chloroform and further
purified with isopropanol and ethanol. Afterward, DNA
treatment was performed with a DNase kit (Invitrogen)
and the RNA content and purity was examined by spectro-
photometry. The RNA was transcribed to cDNA using the
Reverse Transcriptase Core Kit (Eurogentec) on a Thermo-
cycler (Applied Biosystems 2720 Thermocycler). Real-time
PCR was performed on the ABI 7500 Fast Real-Time
PCR device with ABI Taqman probes (Applied Biosystems)
for the following genes: OCT4 (Hs00732896_s1), NANOG
(Hs02387400_g1), HAND1 (Hs00231848_m1), COL2A1
(Hs01064869_m1), CD34 (Hs00990732_m1), RUNX2
(Hs00231692_m1), NESTIN (Hs00707120_s1), SOX9
(Hs00165814_m1), PAX6 (Hs01088112_m1), CERBERUS
(Hs00193796_m1), AFP (Hs00173490_m1), and GATA4
(Hs00171403_m1). GAPDH was selected as endogenous
control. Analysis of the gene expression was done using the
ABI software for gene expression analysis on the ABI 7500
Fast Real-Time device.
Results
The VUB01 cell line was selected for a large-scale slow-
freezing study. Figure 1 shows a comparison of the mean
recovery rates of the different experimental conditions.
When protocol 1 was applied, a successful startup of the
colonies was obtained in all conditions with DMSO.
FIG. 1. Comparison of the recovery ratios at day 7 post-
thawing of the VUB01 cell line under different experimental
conditions. Application of protocol 1 led to a successful
startup of the colonies for all conditions containing di-
methylsulfoxide (DMSO). The best recovery rate was ob-
tained with 5% DMSO and 5% hydroxyethylstarch (HES).
Similar results were obtained with protocol 2; however, the
recovery rates are much higher. The use of ethylene glycol
(EG) was unsuccessful.
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Combination of DMSO with HES had a beneficial effect on
the recovery rate. Especially, the experimental conditions
with 5% DMSO + 5% HES and 10% DMSO + 10% HES had
good recovery rates (17.41% – 0.87% and 5.69% – 0.28%).
Successful conditions were not established with the use of
EG alone or with the addition of HES. Our results (10%
DMSO, 5% DMSO + 5% HES, and 10% DMSO + 10% HES)
are significantly different from each other (2-tailed Student’s
t-test, P < 0.05). A similar profile in the recovery rates can be
seen after application of protocol 2. Again, only conditions
with DMSO in the cryopreservation solution resulted in
successful plates. However, application of the second pro-
tocol led to much higher recovery rates compared with ap-
plication of protocol 1. Recovery rates of 80.83% – 4.04% for
the condition with 5% DMSO + 5% HES and 28.77%– 1.44%
for the condition with 10% DMSO + 10% HES were obtained.
For these 2 conditions, this equals a 5-fold increase in re-
covery ratio. Compared with the results of protocol 1 (10%
DMSO, 5% DMSO + 5% HES, and 10% DMSO + 10% HES),
we again obtained significant different values (2-tailed Stu-
dent’s t-test, P < 0.05). Additionally, all cryopreserved sam-
ples with 5% DMSO + 5% HES and 10% DMSO + 10% HES
were successfully thawed. The use of 10% DMSO not always
led to a successful startup (failure of 1 in 3 samples).
Figure 2 depicts the expansion profile of the hESCs during
3 passages, which were cryopreserved under different ex-
perimental conditions. For both protocols, an unfrozen con-
trol sample was included as a reference. The best expansion
profile using protocol 1 was obtained with 5% DMSO + 5%
HES. Here, a mean amount of 3,980– 199 colonies was ob-
tained after 3 passages. With the unfrozen control sample, a
mean amount of 6,368– 318 colonies was obtained. The ex-
pansion profile of the colonies, cryopreserved with protocol
2, is again better than those cryopreserved with protocol 1.
After 3 passages, the mean amount of colonies was
56,910 – 2,845 for the condition with 5% DMSO + 5% HES.
With the unfrozen control sample, a mean amount of
89,712 – 4,486 colonies was obtained.
The pluripotency of the VUB01 cells cryopreserved using
the best condition (protocol 2, 5% DMSO + 5% HES + 90%
HM) was checked with immunostaining and is shown in Fig.
3. The colonies were positive for SSEA-3, SSEA-4, TRA 1-60,
TRA 1-81, and Oct4. The detailed immunofluorescence pic-
tures clearly show a surface localization of SSEA-3, SSEA-4,
TRA 1-60, and TRA 1-81. The Oct4 staining (isoform A)
shows a general nuclear localization. The colonies also ex-
pressed high amounts of alkaline phosphatase.
Additionally, real-time PCR analysis was performed on
cultured hESCs, on previously frozen and thawed hESCs
(day 7 postthawing), and on their derived EBs to confirm the
results of the immunostaining and to examine the differen-
tiation capacity of the hESCs after freezing. The relative
quantitative gene expression profiles can be found in Fig. 4.
The frozen/thawed hESCs show an equally high, even a
slightly increased expression of Oct4 and Nanog when
compared with the control hESCs. This indicates that there is
no decrease in colony quality related to the cryopreservation.
The derived EBs showed a decrease in expression of Oct4
and Nanog and an increase of several differentiation mark-
ers. Upregulation of Sox9 and Pax6 indicates that differen-
tiation is occurring in the ectodermal lineage. The expression
of Nestin is virtually the same as in the control sample.
Upregulation of Hand1, Col2A1, CD34, and Runx2 indicates
differentiation along the mesodermal lineage. Upregulation
of AFP and GATA4 indicates differentiation along the en-
dodermal lineage. Cer1 is downregulated at this stage.
The best conditions, cryopreservation with 5% DMSO +
5% HES + 90% HM and 10% DMSO + 10% HES + 80% HM,
were repeated with 4 other hESC lines (Fig. 5) to verify the
reproducibility. For all cell lines, similar results were ob-
tained. The application of protocol 2 is consistently better
than the application of protocol 1 and the highest recovery
rates are obtained with 5% DMSO + 5% HES + 90% HM.
The size of the cryopreserved hESC colonies was also ex-
amined, as this is an important factor in the cryopreservation
process. Figure 6 shows an overview of the colony size at
cryopreservation. Colonies frozen with protocol 1 have a
mean size of 0.167– 0.008mm2 and those frozen with pro-
tocol 2 measure 0.0052– 0.0002mm2. Statistical analysis
(Mann–Whitney test, P < 0.05) revealed that these differences
are significant. Additionally, the size distribution of the col-
onies frozen with protocol 2 is much more narrow than those
frozen with protocol 1. Less variation and more uniformity
in clump size were obtained using the second protocol. This
can be deducted from the box-plot data and is confirmed by
the illustrative phase-contrast microscopy pictures.
Discussion
The aim of the present study was to investigate several
slow-freezing–rapid-thawing protocols for hESCs enabling
FIG. 2. Expansion data of the VUB01 cell line, after cryo-
preservation under the different experimental conditions.
The best expansion profile of the human embryonic stem
cells (hESCs) after freezing can be seen in the condition with
5% DMSO and 5% HES. Application of protocol 2 leads to a
better expansion than application of protocol 1.
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the cryopreservation of large amounts of hESCs without
direct liquid nitrogen contact. Although vitrification is
commonly used for the cryopreservation of hESCs and high
survival rates are reported, we decided to focus on slow
freezing in the perspective of large-scale hESC banking. The
inherent high technical requirements of vitrification and,
especially, the need to work with very small volumes to
achieve good results make large-scale vitrification difficult.
However, a new method for bulk vitrification of hESCs was
recently suggested by Li et al. [4,5], using a vitrification vial
with a steel mesh instead of the commonly used open straws.
Nevertheless, as the cryopreservation is performed in open
vials, an increased risk of contamination and cell infection is
present [30].
In the present study, we attempted to eliminate high
amounts of cryoprotectors, serum, or other added sub-
stances and to reduce the risk of contamination during
freezing by the use of closed cryovials. By combining in-
tracellular and extracellular cryoprotectors, both the inner
cell and the cell surrounding are stabilized, which in theory
should lead to a better cell survival once an ideal combi-
nation is found. To our knowledge, this is the first time that
HES is evaluated as a cryoprotector in hESC culture sys-
tems. HES, in combination with DMSO, is widely used for
the cryopreservation of cord blood, bone marrow, and he-
matopoietic stem cells [14,21,22]. For these cell types, it has
FIG. 3. Pluripotency evaluation of the VUB01 hESC line,
frozen with the adapted protocol and 5% DMSO+5% HES+
90% HM. Positive stainings were obtained for all markers. In
the overview image, but more specifically in the detailed im-
ages of SSEA-3, SSEA-4, TRA 1-60, and TRA 1-81, it is clear that
the expression of the markers is localized on the surface, as
anticipated. Immunostaining for Oct4 (Isoform 4A) shows a
broad nuclear localization. (A) SSEA-3; (B) SSEA-4; (C) TRA 1-
60; (D) TRA 1-81; (E) Oct4; (F) alkaline phosphatase staining.
FIG. 4. Real-time PCR data regarding pluripotency and
differentiation capacity of the VUB01 cell line, frozen with
protocol 2 and 5% DMSO + 5% HES + 90% HM. The relative
quantitative gene expression profile of 3 datasets [hESC
control, hESCs at day 7 postthawing, and derived embryoid
bodies (EBs)] are compared with each other. There is a high
expression of Oct4 and Nanog in the thawed hESCs, slightly
higher than in the control hESCs. Additionally, there is no
upregulation of differentiation markers visible. The EBs
show a decrease in Oct4 and Nanog expression, indicating
that differentiation is occurring. Moreover, there is an in-
crease in several differentiation markers, characteristic of the
3 germ layers.
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been proven to be beneficial to use the combination of 5%
DMSO and 6% HES instead of 10% DMSO. It results in a
higher nucleated cell recovery, a better cell viability, and a
higher burst-forming (BFU-E) and colony-forming (CFU-
GM) potential [14]. From a clinical point of view, this re-
duced DMSO protocol also led to less clumping of the cells
at infusion, combined with a reduced incidence and sever-
ity of transfusion-related reactions and improved kinetics of
engraftment. These observations were made with mesen-
chymal and hematopoietic stem cells, and as such, it is in-
teresting to investigate the effect of this cryoprotector on
embryonic stem cells.
We compared the recovery/survival rates of the colonies
detached before freezing either by collagenase IV alone
(protocol 1) or by collagenase IV combined with the cell
dissociation solution (protocol 2). The recovery rate was
calculated at day 7 postthawing/postplating. At this time
point, the mean colony size of previously frozen and un-
frozen control colonies is comparable and morphological
gradual scoring could be easily performed. In general, for
both protocols, 5% DMSO + 5% HES + 90% HM turned out
to be the best solution. However, the recovery rate was much
higher and also significantly different (P < 0.05) when pro-
tocol 2 was applied. This was confirmed in all 5 cell lines
tested.
Analysis of the cryopreservation data using protocol 1 or 2
showed that slow freezing with DMSO was always suc-
cessful. The use of EG had a negative impact on our cryo-
preservation protocols. Similar results were obtained by Ha
et al. [12]. Their study clearly showed that only 5% DMSO in
combination with high amounts of FBS (95%) allowed hESCs
to survive the cryopreservation process, although at a low
recovery rate. However, this protocol could be ameliorated
by combining 5% DMSO with 10% EG and only 50% FBS. Ha
et al. were able to obtain a survival rate of 30.2% and also
observed low recovery rates with EG. However, for our
objective, the use of high amounts of FBS would be in-
acceptable. In our protocol, an HM medium, which contains
only 20% knock-out serum replacement (also known as
synthetic serum), is applied.
In protocol 2, the hESCs were additionally treated with the
cell dissociation solution before freezing. The cell dissocia-
tion solution is a very mild, nonenzymatic, animal-free so-
lution used for cell passaging. It has been previously tested
in combination with hESCs for single-cell passaging with
positive effects [31]. The application of the cell dissociation
solution before freezing reduces the mean hESC clump size.
Moreover, the clump size is more uniform, thereby creating a
mixed population of very small hESC clumps and single cells
before freezing. Subsequently, the penetration of DMSO into
the hESCs and the extracellular stabilization by HES should
more easily occur, thus allowing a faster/better installation
of the osmotic equilibrium and less ice damage. This was
confirmed by our results for all tested cell lines. The combi-
nation of 5% DMSO + 5% HES and 10% DMSO + 10% HES
resulted in higher recovery rates, compared with the single
use of DMSO. Other scientists have also investigated freez-
ing of small clumps and single-cell hESCs [16,18,32,33].
Combinations of 10% DMSO with high amounts of synthetic
serum or 10% DMSO with hESC medium and Rock inhibitor
FIG. 5. Overview of the hESC recovery ratio of 4 different
hESC lines. The highest recovery ratios are consistently ob-
tained with the application of protocol 2 (5% DMSO and 5%
HES).
FIG. 6. Colony size distribution at cryopreservation. Co-
lonies frozen with protocol 2 are much smaller than those
frozen with protocol 1, as can be deducted from the box-plot
data and confirmed by the illustrative phase-contrast mi-
croscopy pictures. Additionally, the hESC clumps are more
uniform in size and show less variation.
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(Y-27632) generally led to good results. Often TrypLE Ex-
press or trypsin/EDTA was used as a dissociative agent and
the Rock inhibitor (mostly 10mM) could be added before,
during, and after the cryopreservation process. Without the
use of Y-27632, the results were rather poor. It has been
postulated that Y-27632 acts by desensitizing the single cells
to go into anoikis upon dissociation. The exact reaction
mechanism of Y-27632 is, at the moment, unknown and a lot
of crosstalks between pathways occur, which makes inves-
tigating this mechanism rather difficult [34]. However, it
should be carefully considered that Y-27632 could also have
negative effects on the cryopreservation of stem cells, such as
a reduced expansion and cell survival as observed for cord
blood stem cells [35] or morphological changes linked with
initiating differentiation observed for mesenchymal stem
cells [36]. In our setup, no Y-27632 was added and good
results were obtained.
As inherent differences between hESC lines [37] exist, we
investigated the effect of our optimized cryopreservation
protocol on 5 hESC lines. Protocol 2 with 5% DMSO and 5%
HES led to the highest recovery rates, ranging from 45.5% for
the H1 cell line to 168.2% for the H9 cell line. It might be
atypical to obtain a recovery rate higher than 100%, but this
simply is due to the fact that the hESC colonies are processed
into smaller clumps during the freezing process, which can
subsequently give rise to a higher number of new colonies at
thawing.
Not only the recovery ratio is important when studying
hESC cryopreservation, also their undifferentiated status,
expansive behavior, and expression profile should be ex-
amined. Analysis of the previously frozen hESC colonies
reveal that they still express high amounts of SSEA-3, SSEA-
4, TRA 1-60, TRA 1-81, Oct4, and ALP, all characteristic
markers of pluripotent hESCs. The expansive capacity of the
different frozen samples is clearly visible in the 3D bar graph.
The condition with the overall best recovery ratio, elicits the
best expansive profile. Less than 5% differentiation occurred
in our best condition. Hence, the use of 5% DMSO in com-
bination with 5% HES not only results in a high recovery
ratio after freezing, but also allows good cell expansion,
which is of key importance for future applications. Real-time
PCR analysis of the EBs showed a decrease in Oct4 and
Nanog expression and an increase in expression of meso-
dermal, endodermal, and ectodermal markers, indicating
their pluripotent cell nature and capacity to differentiate to
the 3 germ layers.
On the basis of our results, we conclude that protocol 2
with 5% DMSO and 5% HES is ideal for slow freezing of
hESCs. In this protocol, the hESCs are detached with colla-
genase IV, treated with the cell dissociation solution to ob-
tain a more uniform size distribution of the colonies, and
slowly frozen in HM medium with only 5% DMSO and 5%
HES. Rapid thawing and equilibration into 0.1M sucrose–
HM medium resulted in a good colony startup and expan-
sion profile. In addition to a minimal amount of synthetic
serum, no additional substances (such as Y-27632) were ad-
ded and a nonenzymatic, animal-free dissociative solution
was used. As HES and the cell dissociation solution are quite
cheap when compared with other possible additions (such as
Y-27632), we suggest that this is an economically feasible
protocol for the freezing of large amounts of hESCs for hESC
banking.
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